DelveInsight

The incidence rate of High-Grade Glioma is 5-10 new diagnoses per 1,000,000 children per year. HGGs accounts for nearly 15-20% of CNS tumours in children and adolescents. It has been observed that HGG is more common in men than in women. The key players in the High-Grade Glioma Market includes BioMimetix, Oncoceutics, Inc., Bristol-Myers Squibb, Istari Oncology, Aadi Bioscience, Sumitomo Dainippon Pharma, Novartis, Kazia Therapeutics, and others. For more details visit: https://www.delveinsight.com/report-store/high-grade-glioma-market

The total diagnosed prevalent population of Familial Hypercholesterolemia (FH) in the 7MM was 965,405 in 2017, which is anticipated to increase by 2030. Also, the diagnosed prevalent population of FH was found to be 244,214 in the United States during the same period. The market size of Familial Hypercholesterolemia in the 7MM was found to be USD 1,069.27 Million in 2017. Emerging therapies and promising organizations are some of the key factors expected to drive the FH market in the coming years, while late diagnosis, differential diagnosis, lack of Homozygous FH (HoFH) are major barriers in the advancement of the Familial Hypercholesterolemia market. The key players in the Familial Hypercholesterolemia market includes Regeneron Pharmaceuticals, Novartis, Arrowhead Pharmaceuticals, NeuroBo Pharmaceuticals, Madrigal Pharmaceuticals, and others. For more information visit: https://www.delveinsight.com/report-store/familial-hypercholesterolemia-type-ii-hyperlipoproteinemia-market

In the 7MM, the total diagnosed prevalent cases of Postpartum Depression in 2017 were 1,134,800. With 609,900 cases, the United States accounts for the highest diagnosed prevalent population of Postpartum Depression. The market size of Postpartum Depression in 7MM was found to be USD 138.75 Million in 2017. Some of the key factors such as increasing cases and increasing awareness of postpartum depression, zulressou2019s positive breastfeeding data, and improvement over conventional therapies are expected to drive the Postpartum Depression Market in the upcoming years. The key players in the Postpartum Depression market include Sage Therapeutics, Marinus Pharmaceuticals, and others. For more details visit: https://www.delveinsight.com/report-store/postpartum-depression-market

The total diagnosed prevalent population of Fibrodysplasia Ossificans Progressiva in the 7MM was 567 in 2017. Females were found to be more affected by Fibrodysplasia Ossificans Progressiva as compared to males. Similarly, a higher prevalence is diagnosed for the age group 20-29. Increase in research and development, upcoming launch and approval of therapies, awareness of disease are some of the key factors expected to drive the Fibrodysplasia Ossificans Progressiva market in the upcoming years. The key players in Fibrodysplasia Ossificans Progressiva Market includes Ipsen, Regeneron Pharmaceuticals, AstraZeneca/Amsterdam UMC, Incyte Corporation, Kyoto University/ Takeda and many others. For more detailed information on Fibrodysplasia Ossificans Progressiva Market, visit: https://www.delveinsight.com/report-store/fibrodysplasia-ossificans-progressiva-fop-market

The total prevalent cases of Dilated Cardiomyopathy in the 7MM are expected to be 2,523,808 in 2020. The Dilated Cardiomyopathy market is expected to grow with a CAGR of 13.1% in the 7MM during the study period (2017u20132030). Increasing prevalence rate, increased healthcare spending, and emerging treatment options are some of the key factors expected to drive the Dilated Cardiomyopathy market in the upcoming years. The key players in the Dilated Cardiomyopathy market include Pfizer, MyoKardia, Capricor Therapeutics, Vericel Corporation, Berlin Cures, Cumberland Pharmaceuticals and many others. For more details visit: https://www.delveinsight.com/report-store/dilated-cardiomyopathy-dcm-market-insights

The total prevalent cases of Prostate Cancer in the 7MM is expected to be 7,494,882 in 2020, and are expected to increase during the study period. The market size of Prostate Cancer is expected to grow at a CAGR of 8.1% during the study period 2017-2030. Increasing use of biomarker testing, rising geriatric population and high prevalence rate of prostate cancer, surge in awareness regarding the treatment of prostate cancer, increase in demand for prostate cancer treatment products are some of the key factors expected to drive the Prostate Cancer market in the upcoming years. AstraZeneca, Bristol-Myers Squibb, Novartis, Myovant Sciences, Janssen Research & Development, Hinova Pharmaceuticals USA, Hoffmann-La Roche, Pfizer/Astellas Pharma, Clovis Oncology, Advantagene Inc., and Merck Sharp & Dohme along with others are the major pharma companies working to fuel the Prostate Cancer market. For more detailed information on Prostate Cancer Market, visit: https://www.delveinsight.com/report-store/prostate-cancer-market

The total prevalent population of Nontuberculous Mycobacteria Infection in 7MM is expected to be 3,95,429 by 2030. The United States accounts for approximately 49% of the total prevalent population in 7MM. The therapeutic market of Nontuberculous Mycobacteria Infection in 7MM is expected to grow at a CAGR of 6.6% during the study period. The key players in the Nontuberculous Mycobacteria Infection market include Insmed Inc., RedHill Biopharma, Novoteris, Savara Inc, Beyond Air and others. For more information visit: https://www.delveinsight.com/report-store/nontuberculous-mycobacterial-ntm-infections-market

The market size of Immune Thrombocytopenia in 7MM was USD 2527.72 Million in 2017. The total prevalent population of Immune Thrombocytopenia in the 7MM is estimated to be approximately 184,676 in 2020. The key players in the Immune Thrombocytopenia market include Octapharma USA, Amgen, CSL Behring, Dova Pharmaceuticals, Rigel Pharmaceuticals, Novartis, Bio Products Laboratory, Takeda, AstraZeneca, Biotest, SK Plasma, Argenx, Kezar Life Sciences, UCB Biopharma, Bristol-Myers Squibb, Principia Biopharma, Protalex and others. For more detailed information visit: https://www.delveinsight.com/report-store/immune-thrombocytopenia-market

The Hunter Syndrome Market is expected to increase with a CAGR of 7.5% in 7MM during the study period (2017-2030). The total diagnosed prevalent population of Hunter Syndrome in 7MM was 1,166 in 2017. The key players in Hunter Syndrome Market include Takeda, JCR Pharmaceuticals, GC Pharma, Regenxbio, Denali Therapeutics, Sangamo Therapeutics, ArmaGen and others. For more details visit: https://www.delveinsight.com/report-store/hunter-syndrome-market

As per DelveInsight, in 2017, the total prevalent population of Adrenoleukodystrophy in the 7MM was 55,242. A higher percentage of diagnosed prevalence was observed for females, in comparison to males, in all the 7MM countries during the study period (2017u20132030). The market size for Adrenoleukodystrophy in the United States was USD 523.26 million in 2017. The market of Adrenoleukodystrophy is expected to experience a significant rise in the coming years. Increased number of potential therapies in the pipeline, awareness about newborn screening programs, increased in the number of childhood cerebral Adrenoleukodystrophy cases are some of the key factors expected to drive the Adrenoleukodystrophy Market in the upcoming years. The key players in the Adrenoleukodystrophy Market include Bluebird Bio, Minoryx Therapeutics, MedDay Pharmaceuticals, Magenta Therapeutics, Orpheris, SOM Biotech and others. For more information visit: https://www.delveinsight.com/report-store/adrenoleukodystrophy-market

DelveInsightu2019s u2018Postpartum Depression (PPD) - Market Insights, Epidemiology and Market Forecast - 2030u2019 report delivers an in-depth understanding of the Postpartum Depression (PPD), historical and forecasted epidemiology as well as the Postpartum Depression (PPD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. Postpartum depression (PPD) is the most common non-psychotic, complication of childbearing affecting approximately 10u201315% of women and as such, represents a considerable public health problem affecting women and their families. The postnatal period is well established as an increased time of risk for the development of serious mood disorders. There are three common forms of postpartum affective illness: the blues (baby blues, maternity blues), postpartum (or postnatal) depression, and puerperal (postpartum or postnatal) psychosis each of which differs in its prevalence, clinical presentation, and management.

The market size of Catheter-Related Bloodstream Infection in the 7MM was USD 694.7 Million in 2017. As per DelveInsightu2019s analysis, the total incident population of Catheter-Related Bloodstream Infection (CRBSI) was found to be 6,69,393 in 7MM in 2017. Competitive landscape, increasing research & development activities, and cost-effectiveness of emerging therapies are some of the key factors expected to drive the Catheter-Related Bloodstream Infection Market in the upcoming years. The key players in the Catheter-Related Bloodstream Infection market include CorMedix, Geistlich Pharma, TauroPharm GmbH, Fresenius Medical Care, Citius Pharmaceuticals and others. For more detailed information, visit: https://www.delveinsight.com/report-store/catheter-related-bloodstream-infection-market

Cardiomyopathy is a general term that refers to the disorders of the cardiac muscle that cause mechanical or electrical dysfunction resulting in dilated, hypertrophic or restrictive pathophysiology. In Cardiomyopathy, the walls of the heart chambers become stretched, thickened or stiff; this affects the heart's ability to pump blood around the body. DelveInsightu2019s u2018Dilated Cardiomyopathy (DCM) - Market Insights, Epidemiology and Market Forecast u20142030u2019 report delivers an in-depth understanding of the Dilated Cardiomyopathy, historical and forecasted epidemiology as well as the Dilated Cardiomyopathy market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom), and Japan.

DelveInsightu2019s u2018Non-Small Cell Lung Cancer (NSCLC) - Market Insights, Epidemiology and Market Forecast - 2030u2019 report delivers an in-depth understanding of the Non-Small Cell Lung Cancer, historical and forecasted epidemiology as well as the Non-Small Cell Lung Cancer market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom), and Japan. The Non-Small Cell Lung Cancer market report provides current treatment practices, emerging drugs, Non-Small Cell Lung Cancer market share of the individual therapies, current and forecasted Non-Small Cell Lung Cancer market size from 2017 to 2030 segmented by seven major markets. The Report also covers current Non-Small Cell Lung Cancer treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses underlying potential of the market.

According to DelveInsight, the therapeutic market of Metabolic Acidosis in 10 emerging markets generated USD 484 Million in 2017 and is expected to change in the forecast period 2017u20132030. The total prevalent cases of Metabolic Acidosis in 10 emerging markets was found to be 1,97,26,410 in 2017. The key players in the Metabolic Acidosis market include Tricida, Advicenne Pharma and others. For more information visit: https://www.delveinsight.com/report-store/metabolic-acidosis-market

According to DelveInsight, the market size of Progressive Supranuclear Palsy in 7MM was found to be USD 10.54 Million in 2017 and is expected to increase during the study period (2017-2030). In 2017, the total prevalent cases of Progressive Supranuclear Palsy were found to be 98,498 in seven major markets. The key players in Progressive Supranuclear Palsy market include AlzProtect, UCB Biopharma, Asceneuron Therapeutics, TauRx Pharmaceuticals and others. For more detailed information visit: https://www.delveinsight.com/report-store/progressive-supranuclear-palsy-market

DelveInsight's "Acute Kidney Injury (AKI) - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Acute Kidney Injury (AKI), historical and forecasted epidemiology as well as the Acute Kidney Injury (AKI) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. The Acute Kidney Injury (AKI) market report provides current treatment practices, emerging drugs, Acute Kidney Injury (AKI) market share of the individual therapies, current and forecasted Acute Kidney Injury (AKI) market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Acute Kidney Injury (AKI) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Familial Chylomicronemia Syndrome Market The total prevalent population of Familial Chylomicronemia Syndrome (FCS) in the 7MM was found to be 5,801 in 2017. The therapeutic market of Familial Chylomicronemia Syndrome in seven major markets was found to be USD 1.0 Million in 2017 which is expected to increase during the study period (2017u20132030). The key players in the Familial Chylomicronemia Syndrome Market include Akcea Therapeutics, Ionis Pharmaceuticals, Arrowhead Pharmaceuticals, Amryt Pharma and others. For more information visit: https://www.delveinsight.com/report-store/familial-chylomicronemia-syndrome-market

According to DelveInsight, the LAG-3-Next Generation Immunotherapy market is expected to generate USD 3,421 Million in the year 2035 with a significant CAGR in the forecast period. NSCLC will occupy the major market share that is 98.81% by 2035. Launch of potential upcoming therapies, the addition of personalised drug therapies with combination therapies for efficacy enhancement, increased funding for R&D expense, understanding of disease and pathogenesis are some of the key factors expected to drive the LAG-3-Next Generation Immunotherapy market in upcoming years. The key players in LAG-3-Next Generation Immunotherapy market include MacroGenics, Zai Lab, Bristol-Myers Squibb, Ono Pharmaceuticals, Immutep, Novartis, Merck, F-star Therapeutics, Regeneron, Xencor, Incyte Biosciences, Agenus, Roche, GlaxoSmithKline, Innovent Biologics (Suzhou) Co. Ltd. and others. For more information visit: https://www.delveinsight.com/report-store/LAG-3-next-generation-immunotherapy-competitive-landscape

Shingles is caused due to a reactivation of varicella zoster virus (VZV) in a person's body. The disease chickenpox is caused by the initial infection with VZV. DelveInsight's "Herpes Zoster - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Herpes Zoster, historical and forecasted epidemiology as well as the Herpes Zoster market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The TIM-3-Next Generation Immunotherapy market is expected to generate USD 1,218 Million in the year 2035. The key players in TIM-3-Next Generation Immunotherapy market include Symphogen, GlaxoSmithKline, Novartis, Bristol-Myers Squibb, Ono Pharmaceuticals, BeiGene, Incyte Biosciences, Agenus, Roche, Eli Lilly and others. For more information visit: https://www.delveinsight.com/report-store/TIM-3-next-generation-immunotherapy-competitive-landscape

DelveInsight's "Adrenoleukodystrophy - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Adrenoleukodystrophy, historical and forecasted epidemiology as well as the Adrenoleukodystrophy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Neoantigen-based Personalized Cancer therapeutic Vaccines are one way to utilize the bodyu2019s immune system to fight cancer. Neoantigens are highly immunogenic as they are not expressed in normal tissues. They can activate CD4 and CD8 T cells to generate immune response and have the potential to become new targets of tumor immunotherapy. NSCLC possesses the maximum market share among various Neo-antigen based cancer vaccine indications in the 7 MM countries. While Brain and Bone cancer will occupy the lowest market share in the overall Neoantigen Cancer Vaccine market. Some of the key companies such as OSE Immunotherapeutics, Immunitor, Gristone Oncology, Neon Therapeutics, Genocea, Targovax, Gradalis, are developing drugs for Neoantigen-based Personalized Cancer therapeutic Vaccines. For more details visit: https://www.delveinsight.com/report-store/neoantigen-based-personalized-cancer-therapeutic-vaccines-competitive-landscape

The Non-Small Cell Lung Cancer market is expected to increase with a CAGR of 10.7% during the study period of 2017-2030. The total Non-Small Cell Lung Cancer incident cases were 484,726 in 7MM in 2017. Increase use of biomarker testing, increase incidence of NSCLC, increase in the mutation-specific trials activity & approval, and competitive landscape are some of the leading factors expected to drive the Non-Small Cell Lung Cancer market in the coming years. The key players in Non-Small Cell Lung Cancer market include Novartis, Merck, KGaA, Eli Lilly and Company, Hoffmann-La Roche, Xcovery, BeyondSpring Pharmaceuticals, OSE Immunotherapeutics, Sanofi, Takeda, AbbVie and others. For more detailed information visit: https://www.delveinsight.com/report-store/non-small-cell-lung-cancer-market